Cash Flow Stocks Worth A Closer Look As Bond Yields Stay High

Global bond market volatility has pushed government yields in the US, Canada and Euro Area to elevated levels, which makes dependable cash generation even more valuable to investors seeking stability. When markets focus on income and resilience, stocks that produce strong cash flows yet trade below fair value can attract renewed attention. This article highlights 3 stocks from the Undervalued Stocks Based On Cash Flows screener that fit that theme.

The 3 stocks below are a sample of what this idea can look like in practice. The full screen surfaces 44 more companies with equally compelling cash flow stories that are not covered here. To go deeper into this theme, analyze and filter for your own highest conviction ideas directly in the Undervalued Stocks Based On Cash Flows screener.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals is a commercial stage radiopharmaceutical company that develops precision imaging agents and targeted therapies such as Illuccix for prostate cancer diagnosis and late stage candidate TLX591, which are central to the cash flow potential that anchors its inclusion in the Undervalued Stocks Based On Cash Flows screener. The business currently earns most of its revenue from the Precision Medicine segment at about $704 million, with Manufacturing Solutions contributing around $277 million, indicating a model that already generates meaningful cash while supporting its pipeline. Telix has a market cap of roughly A$5.3 billion.

Investors looking for exposure to cash generative healthcare growth may find Telix Pharmaceuticals worth a closer look. Commercial products like Illuccix and Gozellix are already supporting revenue and EBITDA, and late stage assets such as TLX591 offer additional potential cash flow streams if trial and regulatory milestones go to plan. At the same time, high R&D spending, an SEC subpoena over disclosures, pricing pressure in prostate imaging and an operating loss at the RLS distribution arm show that execution risk is real. For investors comfortable weighing strong cash generation against these uncertainties, the full Telix story goes much deeper than headline figures.

Telix Pharmaceuticals already generates meaningful cash, yet the real story lies in how that cash could reshape its pipeline and balance future risks. Get the full picture in the 3 key rewards and 2 important warning signs (1 is major!)

Build your own cash flow shortlist

Telix Pharmaceuticals and the other two stocks in this article all came from a single Simply Wall St screener, but the real opportunity is in shaping your own filters. Use our flexible Screener to mix cash flow strength, valuation, growth and risk checks, or jump straight into our curated Investing Ideas for ready made starting points.

Lynas Rare Earths (ASX:LYC)

Lynas Rare Earths is an integrated rare earth miner and processor that extracts and refines rare earth oxides like neodymium and praseodymium from its Mt Weld mine in Western Australia and advanced materials plant in Gebeng, Malaysia, a cash flow centric business that aligns closely with the Undervalued Stocks Based On Cash Flows theme. The company generates about A$716 million in revenue from its Rare Earth Operations segment, which covers mining, concentration and downstream processing. Lynas Rare Earths has a market cap of roughly A$16.3b, reflecting its role as a major non Chinese supplier in the global rare earth supply chain.

Investors looking for cash flow tied directly to the electrification trend may find Lynas Rare Earths worth a closer look. Its rare earth production from Mt Weld and downstream processing in Malaysia link directly to demand for magnets used in electric vehicles and wind turbines, and recent earnings momentum and an 11.5% net margin point to a business that is already converting that demand into cash. At the same time, heavy reliance on a narrow set of products, regulatory risk in Malaysia and a premium P/S multiple mean the story is not without tension. The real question is whether the forecast cash flows and Simply Wall St DCF justified valuation gap can outweigh those risks.

Lynas Rare Earths is already converting rare earth demand into cash, yet the real story may sit in the details of its pricing power, margins and product mix. Get the full context in the analysis report for Lynas Rare Earths

WiseTech Global (ASX:WTC)

WiseTech Global develops CargoWise, a cloud based logistics platform that helps freight forwarders, customs brokers and other logistics providers manage the movement and storage of goods, which creates recurring SaaS and implementation cash flows that align closely with the Undervalued Stocks Based On Cash Flows theme. The company reports revenue across the Americas at about US$451 million, Asia Pacific at roughly US$255 million and Europe, Middle East and Africa at around US$364 million, reflecting a broad global customer base. WiseTech Global has a market cap of about A$14.1 billion.

WiseTech Global brings together a sticky, transaction based CargoWise platform, a growing suite of logistics software and a recurring revenue engine that sits at the heart of the cash flow story behind its DCF assessed undervaluation. Forecast earnings growth in the mid 20% range and a clear path to higher return on equity are key elements investors may monitor when assessing recent margin pressure and a large one off loss that weighed on the latest numbers. At the same time, higher leverage after the E2open deal, an ACCC competition investigation and the shift to a new pricing model all add execution and regulatory risk. The central consideration is whether that recurring cash flow base can more than offset these pressures as the integration and product roadmap progress.

WiseTech Global’s recurring cash engine and DCF assessed undervaluation could be masking an under appreciated growth story that investors have not fully priced in yet. Get the context behind that gap in the analyst forecasts for WiseTech Global

Seeking Fresh Alternatives Before Others Catch On

New ideas move fast. By the time the crowd notices a breakout, the best entry points can be gone. Scan these fresh, under the radar lists while it matters and consider taking action promptly.

• Spot cash rich companies quietly building momentum before they start gaining broader attention by scanning the curated list of solid balance sheet and fundamentals (21 results) that most investors are still ignoring.
• Track where AI strength aligns with real profits, not hype, by screening the hand picked 76 profitable AI stocks that aren't just burning cash before the strongest trends become widely recognized.
• Review the focused 28 best rare earth metal stocks to stay informed about potential metal supply constraints while these producers remain under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com